hop on

Houston METRO partnership receives $1.5M federal grant to bring electric buses to the Third Ward

The electric buses are expected to debut in about a year. Photo via ridemetro.org

Get ready to ride a new fleet of zero emission shuttles from Houston METRO. Global consulting firm AECOM and METRO partnered on new electric bus initiative and have recently been granted $1.5 million from the Federal Transit Administration to bring the service to Texas Southern University, University of Houston, and Houston's Third Ward neighborhood.

The grant was awarded through the FTA's Accelerating Innovative Mobility, or AIM, initiative and was one of only 25 initiatives across the U.S. to receive FTA funding. The new buses are expected to be fully operational in spring of next year.

"The shuttle will connect to METRO buses and light rail and be studied for potential use in urban, suburban, and rural environments," says Kim Williams, METRO's chief innovation officer, in a news release. "Our industry continues to evolve with new technology that prioritizes clean air quality."

AECOM will manage, plan, and provide engineering support services for the project for METRO, which is a founding member of AECOM's Automated Bus Consortium.

"We're thrilled to work with our longtime partner, METRO, on this exciting AIM initiative and to further progress mobility and innovation in the transit industry while helping our clients achieve their sustainability goals," says Andrew Bui, AECOM's vice president of global transportation electrification, in the release.

"This project will strengthen our ongoing efforts through our Automated Bus Consortium and contribute to Houston's already expansive work in deploying emerging technologies," Bui adds.

The vehicle will be provided by the project's partner Phoenix Motorcars, which makes zero emission, all-electric vehicles via software from EasyMile, a leader in cutting-edge autonomous technology.

Trending News

Building Houston

 
 

Dr. Peter Hotez and Dr. Maria Elena Bottazzi have been recognized by Fast Company for their leadership in developing low-cost COVID vaccine. Photo courtesy of Texas Children's

This week, Fast Company announced its 14th annual list of Most Creative People in Business — and two notable Houstonians made the cut.

Dr. Peter Hotez and his fellow dean of the National School of Tropical Medicine at Baylor College of Medicine, Dr. Maria Elena Bottazzi, were named among the list for “open sourcing a COVID-19 Vaccine for the rest of the world.” The list, which recognizes individuals making a cultural impact via bold achievements in their field, is made up of influential leaders in business.

Hotez and Bottazzi are also co-directors for the Texas Children's Hospital's Center for Vaccine Development -one of the most cutting-edge vaccine development centers in the world. For the past two decades it has acquired an international reputation as a non-profit Product Development Partnership (PDP), advancing vaccines for poverty-related neglected tropical diseases (NTDs) and emerging infectious diseases of pandemic importance. One of their most notable achievements is the development of a vaccine technology leading to CORBEVAX, a traditional, recombinant protein-based COVID-19 vaccine.

"It's an honor to be recognized not only for our team's scientific efforts to develop and test low cost-effective vaccines for global health, but also for innovation in sustainable financing that goes beyond the traditional pharma business model," says Hotez in a statement.

The technology was created and engineered by Texas Children's Center for Vaccine Development specifically to combat the worldwide problem of vaccine access and availability. Biological E Limited (BE) developed, produced and tested CORBEVAX in India where over 60 million children have been vaccinated so far.

Earlier this year, the doctors were nominated for the 2022 Nobel Peace Prize for their research and vaccine development of the vaccine. Its low cost, ease of production and distribution, safety, and acceptance make it well suited for addressing global vaccine inequity.

"We appreciate the recognition of our efforts to begin the long road to 'decolonize' the vaccine development ecosystem and make it more equitable. We hope that CORBEVAX becomes one of a pipeline of new vaccines developed against many neglected and emerging infections that adversely affect global public health," says Bottazzi in the news release from Texas Children's.

Fast Company editors and writers research candidates for the list throughout the year, scouting every business sector, including technology, medicine, engineering, marketing, entertainment, design, and social good. You can see the complete list here

.

Trending News